You are here

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Last updated on February 22, 2019

Study Location
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004 China
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and/or Female subjects with Hemophilia A.

- Subjects/parents/legal representatives must be able to comply with registry procedures
(informed consent/assent process, clinical visits, reporting of infusion and bleed
data, reporting of adverse events, etc).

- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative, parent(s)/legal guardian) has
been informed of all pertinent aspects of the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Presence of any other bleeding disorder in addition to hemophilia A.

- Treatment with immunomodulatory therapy (e.g., intravenous immunoglobulin, routine
systemic corticosteroids, cyclosporins, anti-TNF agents) within 30 days prior to study
entry or planned use for the duration of their study participation.

- Subjects with a past history of, or current factor VIII inhibitor. For
laboratory-based assessments, any Bethesda inhibitor titer greater than the
laboratory's normal range or ?0.6 BU/mL.

- Subjects with known hypersensitivity to the active substance or to any of the
excipients of Xyntha.

- Subjects with a known hypersensitivity to Chinese Hamster Ovary cell proteins.

- Unwilling or unable to follow the terms of the protocol.

- Any condition which may compromise the subject's ability to comply with and/or perform
study-related activities or that poses a clinical contraindication to study
participation (these conditions include, but are not limited to, inadequate medical
history to assure study eligibility; expectation of poor compliance in provision of
observations for study-related documentation), in the opinion of the Investigator.

- Participation in other studies involving investigational drug(s) (Phases 1-4) within
30 days before the current study begins and/or during study participation (exception
for studies on Xyntha).

- Subjects who are investigational site staff members directly involved in the conduct
of the study and their family members, site staff members otherwise supervised by the
Investigator, or subjects who are Pfizer employees directly involved in the conduct of
the study.

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now